Testing Chemotherapy versus Chemotherapy plus Radiotherapy Prior to Limited Surgery for Early Rectal Cancer
This phase III trial compares the effect of the combination of fluorouracil, oxaliplatin, and leucovorin calcium (FOLFOX) or capecitabine and oxaliplatin (CAPOX) followed by limited surgery with transanal endoscopic surgery (TES) versus chemoradiation followed by TES for the treatment of early stage rectal cancer. The usual approach for patients who are not in a study is surgery to remove the rectum or treatment with chemotherapy and radiation therapy, followed by surgery. Fluorouracil stops cells from making deoxyribonucleic acid (DNA) and it may kill tumor cells. Leucovorin is in a class of medications called folic acid analogs. When used with fluorouracil, it enhances the effects of this chemotherapy drug. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell’s DNA and may kill cancer cells. CAPOX is a combination of two drugs (capecitabine and oxaliplatin) and used as standard chemotherapy in treatment of rectal cancer. CAPOX works by damaging the DNA in tumor cells, and may cause the cells to stop growing and die. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. This study will help researchers find out if chemotherapy with FOLFOX or CAPOX prior to surgery works better, the same, or worse than the usual approach and improves the quality of life in patients with early rectal cancer.
Inclusion Criteria
- Histologically confirmed invasive, well-moderately differentiated rectal adenocarcinoma, mismatch repair proficient
- MRI stage: * cT1 not eligible for transanal surgery alone as per National Comprehensive Cancer Network (NCCN) guidelines, (including but not limited to T1 tumors > 2 cm in size, positive margin, tumor depth SM3 invasion to the lower third of the submucosal level). or * cT2-T3a
- cN0 stage based on pelvic MRI – including absence of radiographic evidence of mesorectal nodal metastasis, tumor deposits or extramural venous invasion (EMVI)
- M0 stage based on no evidence of metastatic disease by CT imaging of chest, abdomen and pelvis
- Mid to low-lying tumor eligible for transanal excision in the opinion of the treating surgeon
- Medically fit to undergo radical TME surgery as per treating surgeon’s decision
- Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French or Spanish. The baseline assessment must be completed within required timelines, prior to enrollment. Inability (lack of comprehension in English or French or Spanish, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the participant ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the participant ineligible
- Age of at least 18 years
- No contraindications to protocol chemotherapy
- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (must be done within 30 days prior to enrollment)
- Platelet count ≥100 x 10^9/L (must be done within 30 days prior to enrollment)
- Bilirubin < 1.5 upper limit of normal (ULN), excluding Gilbert’s syndrome (must be done within 30 days prior to enrollment)
- Estimated creatinine clearance of ≥ 50 ml/min (must be done within 30 days prior to enrollment)
- The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 (or Karnofsky ≥ 60%)
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
- Must be accessible for treatment and follow up. Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, follow-up and response assessments
- Patients must agree to return to their primary care facility for any adverse events which may occur through the course of the trial
- Males and females of reproductive potential must have agreed to use a highly effective contraceptive method during and for 9 months after completion of chemotherapy. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
- Women of childbearing potential will have a pregnancy test to determine eligibility as part of the pre-study evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
Exclusion Criteria
- Pathologic high-risk factors on diagnostic biopsy: high histologic grade (poorly differentiated), mucinous or signet ring histology
- Patients with visible pelvic sidewall nodes on MRI
- Patients with unequivocal determination of nodal disease that, in the opinion of the investigator, would prohibit protocol therapy administration
- Previous pelvic radiation for any reason, including brachytherapy alone
- Patients who have had primary lesion excised prior to enrollment. If a patient has had partial excision prior to enrollment, there must be gross residual disease endoscopically for patient to be eligible
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Prior treatment for rectal cancer
- Patients with known dihydropyrimidine dehydrogenase deficiency (DYPD)
- Potential trial participants should have recovered from clinically significant adverse events of their most recent therapy/intervention prior to enrollment
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- Any contra-indications to undergo MRI imaging
- Presence of anterior lesions above or near peritoneal reflection rendering the patient ineligible for a transanal tumor excision
- T3 tumors invading or abutting the internal sphincter.
Additional locations may be listed on ClinicalTrials.gov for NCT06205485.
Locations matching your search criteria
United States
Arizona
Phoenix
California
Irvine
Los Angeles
Orange
Delaware
Millville
Newark
Rehoboth Beach
Georgia
Atlanta
Illinois
Aurora
Chicago
Danville
DeKalb
Effingham
Geneva
Mattoon
Urbana
Warrenville
Indiana
Crown Point
Dyer
Hobart
Munster
Valparaiso
Louisiana
New Orleans
Massachusetts
Burlington
Michigan
Clinton Township
Detroit
Grand Rapids
Jackson
Kalamazoo
Novi
West Bloomfield
Minnesota
Bemidji
Nevada
Reno
New Hampshire
Lebanon
New Mexico
Albuquerque
North Carolina
Greenville
North Dakota
Bismarck
Fargo
Ohio
Centerville
Cincinnati
Dayton
Franklin
Greenville
Troy
West Chester
Oregon
Clackamas
Gresham
Newberg
Oregon City
Portland
Tualatin
Pennsylvania
Chadds Ford
South Dakota
Sioux Falls
Tennessee
Germantown
Nashville
Vermont
Saint Johnsbury
Washington
Seattle
Vancouver
Wisconsin
Eau Claire
Marshfield
Minocqua
Rice Lake
Stevens Point
Weston
PRIMARY OBJECTIVE:
I. To compare the complete clinical response (cCR) rate and primary quality of life (QOL) endpoint defined as the rate of major low anterior resection syndrome (LARS) at 12 months after restaging between a strategy of induction chemotherapy and chemoradiotherapy followed by TES for patients with cT1-3aN0 rectal adenocarcinoma.
SECONDARY OBJECTIVES:
I. To compare total mesorectal excision (TME) free survival among patients treated with induction chemotherapy versus chemoradiotherapy.
II. To compare disease free survival among patients treated with induction chemotherapy versus chemoradiotherapy.
III. To compare overall survival among patients treated with induction chemotherapy versus chemoradiotherapy.
IV. To compare rate of downstaging to ypT0/1N0/X among patients treated with induction chemotherapy versus chemoradiation.
V. To compare bowel, bladder, sexual function and QOL in patients treated with induction chemotherapy versus chemoradiation.
VI. To evaluate the toxicity and safety of induction chemotherapy and chemoradiation.
VII. To validate the magnetic resonance tumor regression grade (MR-TRG) in patients with T1-T3a rectal adenocarcinoma.
TERTIARY OBJECTIVES:
I. To describe the circulating tumor DNA dynamics of patients treated with organ sparing therapy.
II. To describe the sensitivity and specificity of circulating tumor DNA to detect locoregional and distant recurrence in patients treated with organ-preserving intent for cT1-3aN0 rectal cancer.
III. To explore relationships between tumor response, adverse events, and quality of life with radiotherapy planning technique (3DCRT vs IMRT), plan minor and major deviations, and doses to organs at risk.
IV. To explore relationship between MR-TRG regression grade and circulating tumor DNA dynamics.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients may receive fluorouracil intravenously (IV) over 46-48 hours on days 1 and 2, leucovorin IV over 2 hours on day 1, and oxaliplatin IV over 2 hours on day 1 of each cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternatively receive capecitabine orally (PO) for 14 days and oxaliplatin IV over 2 hours on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo TES followed by observation. Patients undergo magnetic resonance imaging (MRI), computed tomography (CT), and colonoscopy throughout the trial. Patients also undergo rectal endoscopy and digital rectal exams (DRE) on the trial. Additionally, patients undergo blood sample collection and may undergo tissue biopsy throughout the trial.
ARM II: Patients undergo radiation therapy daily 5-7 days a week for up to 6 weeks. Patients also receive capecitabine PO twice daily (BID) or fluorouracil IV on the same days as radiation therapy. Patients then undergo TES followed by observation. Patients undergo MRI, CT, and colonoscopy throughout the trial. Patients also undergo rectal endoscopy and DRE on the trial. Additionally, patients undergo blood sample collection and may undergo tissue biopsy throughout the trial.
After completion of study treatment, patients are followed up at every 4 months for 2 years, then every 6 months for 1 year, and every year for 2 years.
Trial PhasePhase III
Trial Typetreatment
Lead OrganizationCanadian Cancer Trials Group
Principal InvestigatorHagen F Kennecke
- Primary IDCCTG-CO32
- Secondary IDsNCI-2023-10515, CO.32
- ClinicalTrials.gov IDNCT06205485